There are 360 resources available
23P - Enriching for response: patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material
Presenter: Gregory Vladimer
Session: Poster Display
141P - Efficacy and Safety of Tislelizumab Combined with Targeted Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-world Study
Presenter: Longrong Wang
Session: Poster Display
24P - The predictive and prognostic role of single nucleotide gene variants in PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
Presenter: Andrea Boutros
Session: Poster Display
142P - CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom.
Presenter: Kevin Franks
Session: Poster Display
143P - Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A single-arm phase II trial
Presenter: Xuhua Duan
Session: Poster Display
26P - Impact of SF3B1 mutation on response to immunotherapy
Presenter: Byungho Lim
Session: Poster Display
144P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): a single-arm, phase 2 trial
Presenter: Shi Yan
Session: Poster Display
27P - Gene ontology enrichment analysis of peripheral CD3+CD4+T-cells predicts the immune-mediated behavior of melanoma
Presenter: Dimitrios Ziogas
Session: Poster Display